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Aim of the study: The BRAF inhibitor 
vemurafenib has improved progres-
sion-free survival and overall survival 
in patients with BRAFV600-mutation- 
positive metastatic melanoma. Here 
we present the results of an open-la-
bel safety study with vemurafenib in 
patients with metastatic melanoma 
enrolled in Polish oncological centres. 
Material and methods: Patients with 
untreated or previously treated Stage 
IIIC/IV BRAFV600 mutation-positive 
melanoma were treated with oral 
vemurafenib in an initial dose of 
960 mg twice daily. Assessments for 
safety and efficacy were made every 
28 days. For the survival analysis the 
Kaplan-Meier estimator was used 
with the log-rank tests for bivariate 
comparisons. 
Results: In total, 75 Polish patients 
were enrolled in the safety study 
across four centres. At data cut-off, 
28 patients died (37%), mainly (26) 
due to disease progression; 33 (44%) 
patients continued vemurafenib after 
disease progression. The objective re-
sponse rate was 46%, including two 
patients with a  complete response 
and 29 with a partial response. Medi-
an progression-free survival was 7.4 
months. The one-year overall survival 
rate was 61.9% (median overall sur-
vival was not reached). Seventy-three 
(97.3%) patients reported adverse 
events (AEs), and grade 3–5 toxicity 
was reported in 49.4% (37) patients. 
The most common AEs were: skin le-
sions (including rash and photosensi-
tivity), arthralgia, and fatigue. 
Conclusions: The overall safety pro-
file and response rate of vemurafenib 
were comparable to those reported 
in previous studies of this drug. Our 
study confirmed the value of well-es-
tablished prognostic features for over-
all survival, such as initial LDH (lactate 
dehydrogenase) level and AJCC stag-
ing.
Key words: melanoma, metastatic, ve-
murafenib, BRAF inhibition.
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Introduction
BRAF inhibitors are a currently the standard of care in the treatment of 
patients with advanced melanomas harbouring the BRAF V600 mutation. 
Vemurafenib was the first molecular targeting agent acting on the mutat-
ed BRAF kinase, which demonstrated improvement of overall survival (OS) 
in a phase III randomised trial. In the study comparing vemurafenib and 
dacarbazine in untreated stage IV and unresectable stage IIIC patients with 
BRAF-mutated melanomas, vemurafenib demonstrated rapid objective re-
sponses in approximately 50% of cases, but control of the tumour growth 
was observed in up to 90% of cases [1]. Progression-free survival (PFS) was 
6.9 months in the vemurafenib arm versus 1.6 months in the dacarbazine 
arm, and median OS was 13.6 months [1, 2]. The results of this study led to 
worldwide approval of vemurafenib for the therapy of advanced BRAF-mu-
tated disease. Recently in a large safety study with more than 3000 patients, 
the safety profile and efficacy of vemurafenib were confirmed in real-world 
clinical practice [3]. As the general results of this open-label, multicentre 
study have been already published, we report here the detailed outcomes of 
patient cohorts treated in Polish centres only.
Material and methods
In this open-label study (MO25515, NCT01307397) 75 patients from four 
Polish oncological centres were included to assess the safety and efficacy 
of vemurafenib in advanced (unresectable stage IIIC or stage IV) melano-
ma harbouring BRAF V600 mutation confirmed with the cobas 4800 BRAF 
V600 Mutation Test (Roche Molecular Systems, Branchburg, NJ, USA). The 
eligible patients were treated with oral vemurafenib in an initial dose of 
960 mg twice daily until disease progression (treatment after progression 
was allowed after a joint decision by the investigator and the sponsor), 
unacceptable toxicity, consent withdrawal, or death [3]. The rules for dose 
modifications and interruptions were described previously [3]. The patient 
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characteristics are presented in Table 1. Thirty-six (48%) 
patients underwent prior systemic therapy (including 6 pa-
tients after ipilimumab failure). None of the patients was 
previously treated with BRAF or MEK inhibitor. Seven pa-
tients (9.3%) had brain metastases (stable, asymptomatic 
after previous local therapy) at the time of therapy start. 
The primary end-point of the trial was safety. Patients 
were assessed every 28 days. The secondary variables 
comprised objective response (evaluated by investigators 
using Response Evaluation Criteria in Solid Tumours RE-
CIST version 1.1), progression-free survival (PFS, calculated 
from the date of start of vemurafenib therapy to date of 
progression or death), and overall survival (OS, calculated 
from the date of start of vemurafenib therapy to the date 
of death, living patients were censored). For survival analy-
sis the Kaplan-Meier estimator was used with the log-rank 
tests for bivariate comparisons. Statistical analyses were 
done with SAS (version 9.2) software.
Results
All 75 of the enrolled patients started therapy with ve-
murafenib from October 2011 to June 2012. We present in-
terim analysis prepared on 28 July 2014 with a cut-off date 
on 31 Jan 2013. Forty-two (56%) discontinued therapy, with 
33 due to progressive disease, one due to adverse events, 
and three due to death.
The best confirmed responses were as follows: two 
patients (3%) had complete response, 29 (43%) partial re-
sponse, 30 (45%) stable disease, and six (8%) had disease 
progression. Median duration of response was 7.4 months 
(95% CI: 5.7–9.2). Only eight patients received further sys-
temic therapy (chemotherapy only) after discontinuation 
of vemurafenib. 
Median PFS time was 7.4 months (95% CI: 5.5–9.2), and 
one-year PFS rate was 26.5% (95% CI: 15.3–37.8). Progres-
Table 1. Patients’ characteristics (n = 75)






Age (median, years) 53
Age < 65 years 
Age ≥ 65 years 
65 (86.7)
10 (13.3) 
ECOG 0–1 at baseline ECOG ≥ 2 at baseline 72 (96.0) 
3 (4.0) 
Normal LDH at baseline/screening 
Elevated LDH at baseline/screening 
43 (57.3) 
32 (42.7) 
Patients with brain metastases at baseline 



























 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
G1 N = 43 N = 42 N = 39 N = 38 N = 33 N = 32 N = 31 N = 30 N = 19 N = 19 N = 16 N = 12 N = 8 N = 4 N = 4 N = 1 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0
G2 N = 32 N = 31 N = 27 N = 24 N = 15 N = 14 N = 11 N = 11 N = 7 N = 6 N = 5 N = 2 N = 2 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0
Normal LDH at baseline/screening
Elevated LDH at baseline/screening
Censored: normal LDH
Censored: elevated LDH
Fig. 1. PFS depending on LDH level at the treatment start
Number of Patients at Risk                          Progression free survival (months)
sion-free survival significantly correlated with initial lac-
tate dehydrogenase level (median PFS in the LDH normal 
subgroup was 10.9 months [95% CI: 7.5– ] vs. 3.8 months 
[95% CI: 3.6–7.2] in the LDH elevated subgroup) (Fig. 1), 
and the presence of brain metastases at baseline (median 
PFS was 3.7 months [95% CI: 3.6–9.3] in the brain metasta-
ses subgroup vs. 7.5 months [95% CI: 5.6–10.3] in patients 
without brain metastases). For M1 stage subgroups me-
dian PFS times were as follows: 7.4 months (95% CI: 1.4–) 
in the M1a subgroup, 10.9 months (6.9–) in the M1b sub-
group, and 7.4 (95% CI: 4.6–8.3) in the M1c subgroup. 
Median OS was not reached; the one-year OS rate was 
61.9% (95% CI: 50.1–73.6). OS significantly correlated with 
initial lactate dehydrogenase level (the one-year OS rate 
was 85.1% [74.0–96.1] in the subgroup with normal LDH 
and 31.4% [95% CI: 14.0–48.9] in the subgroup with elevat-
ed LDH [Fig. 2]), and M1 stage (one-year OS rate was 77.8% 
[95% CI: 50.6–104.9] in the M1a subgroup, 75.0% [95% CI: 
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45–105] in the M1b subgroup, and 57% [95% CI: 42.9–71.0] 
in the M1c subgroup). The presence of asymptomatic brain 
metastases, stable after previous therapy at baseline, had 
no significant impact on OS. 
At the time of data cut-off 28 patients died (37%), main-
ly (26) due to disease progression. Thirty-three (44%) pa-
tients continued vemurafenib after disease progression.
Due to adverse events (AEs) 44 patients (57%) needed 
at least one dose modification (reduction or interruption), 
and 28 patients (37%) needed dose reduction. 97.3% (73) 
of patients had at least one AE, and grade 3–5 toxicity 
was reported in 49.4% (37) patients. The most common 
AEs were as previously reported: skin lesions (including 
rash and photosensitivity), arthralgia, and fatigue. Table 2 
summarises AEs occurring in at least 10% of patients, and 
Table 3 shows AEs at grade 3–4. Eight patients (10.7%) de-
veloped cutaneous squamous cell carcinoma (cuSCC), and 
two – new primary melanomas.
Discussion
The constitutive hyperactivation of the RAS/RAF/MEK/
ERK pathway (also termed the Mitogen Activated Protein 
Kinase – MAPK pathway) has been identified in the major-
ity of melanomas as the critical player in the regulation of 
cell proliferation, invasion, and survival [1, 2, 4]. In 50–70% 
of cases this genetic background is achieved via oncogen-
ic mutation of the BRAF gene, mainly V600E point muta-
tion. Vemurafenib is the first BRAF inhibitor class agent 
approved worldwide for therapy of advanced BRAF-mu-
tated melanoma, and has demonstrated improvement 
in OS and PFS as compared to dacarbazine. Thereafter, 
BRAF inhibitors (vemurafenib and dabrafenib) have be-
come the worldwide standard of care for the majority of 
BRAF-mutant metastatic melanomas (especially estab-
lished in patients with high tumour burden or progression 
after immunotherapy). The data presented in our analysis 
confirm other long-term follow-up studies demonstrating 
Table 2. Adverse events grades 3 and 4 by system organ class and 
preferred term 






Number of patients with at least one AE 35 (46.7) 0


















































































Fatigue 1 (1.3) 0
Arthralgia 1 (1.3) 0
Convulsion 1 (1.3) 0





















 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
G1 N = 43 N = 43 N = 42 N = 41 N = 40 N = 38 N = 37 N = 36 N = 33 N = 31 N = 28 N = 24 N = 22 N = 15 N = 11 N = 5 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0
G2 N = 32 N = 31 N = 30 N = 28 N = 24 N = 21 N = 19 N = 17 N = 15 N = 11 N = 10 N = 10 N = 8 N = 5 N = 2 N = 1 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0 N = 0
Normal LDH at baseline/screening
Elevated LDH at baseline/screening
Censored: normal LDH
Censored: elevated LDH
Fig. 2. OS depending on LDH level at the treatment start
Number of Patients at Risk                                                Time (months)
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median PFS more than six months, and approximately 
one fourth of patients were still alive after a longer period 
of time [2, 5]. However, the future of monotherapy with 
BRAF inhibitors is limited due to the relatively short dura-
tion of response in the majority of patients. The addition 
of a MEK inhibitor to a BRAF inhibitor enhances inhibition 
of tumour growth and delays acquired resistance [6]. The 
results from recently published three phase III studies pro-
vide convincing evidence that combination therapy with 
either vemurafenib and cobimetinib or dabrafenib and 
trametinib will become a new standard treatment for ad-
vanced BRAF-mutant melanoma. These randomised trials 
report median progression-free survival ranging from 9.3 
to 11.4 months in combination-therapy groups. In addition, 
higher response rates (64–68%) have been achieved with 
no additional overall toxicity [7–9].
Nevertheless, the current study demonstrates on a na-
tional level the efficacy of vemurafenib monotherapy in 
a group of patients with advanced melanoma with eligibility 
criteria similar to routine practice and requirements for re-
imbursement of vemurafenib therapy in Poland. The overall 
survival data from this study are very encouraging, especial-
ly taking into account that almost 50% of the patients were 
treated with previous systemic therapy. Moreover, our study 
confirmed the value of well-established prognostic features 
for overall survival such as initial LDH level and AJCC stag-
ing [10, 11]. The presence of stable brain metastases had no 
impact on overall survival in our patients, which confirms 
the activity of vemurafenib for controlling brain lesions and 
implies that the mechanism of disease progression is equal-
ly related to the lesions outside the central nervous system 
[12]. The fact that vemurafenib was continued in 44% of 
patients after objective disease progression may also have 
a positive impact on survival [13]. 
The safety profile observed was consistent with that 
reported in previous studies, with cutaneous manifesta-
tions, arthralgia, and fatigue as the most common AEs. 
The number of patients with grade 3 or 4 treatment-relat-
ed adverse events was up to 50%, but only two patients 
discontinued therapy due to unacceptable toxicity. Photo-
sensitivity (related probably to the chemical structure of 
the vemurafenib molecule, not to BRAF inhibition per se) 
is commonly reported during vemurafenib therapy, where-
as pyrexia (characteristic for dabrafenib) was rarely noted. 
cuSCC occurred in approximately 11% of patients, and their 
pathogenesis can be related to paradoxical activation of 
the MAPK pathway in BRAF wild-type cells during selective 
BRAF V600 mutant kinase inhibitor therapy. Keratoprolif-
erative lesions often require additional surgery, and their 
frequency implies careful skin examinations every four 
weeks during vemurafenib therapy.
To summarise, our analysis confirms the efficacy of ve-
murafenib in a large group of Polish patients treated with-
in the frames of a treatment-use clinical trial. The adverse 
events were manageable, and the number of cuSCCs was 
even lower than in phase II–III clinical trials [4, 14]. The 
understanding of the mechanisms of resistance to BRAF 
inhibitors monotherapy and development of combination 
strategy for overcoming early disease progression is the 
most important issue for the immediate future in the ther-
apy of advanced melanoma. 
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